Cite
APA Citation
Hay, A. E., Murugesan, A., DiPasquale, A. M., Kouroukis, T., Sandhu, I., Kukreti, V., Bahlis, N. J., Lategan, J., Reece, D. E., Lyons, J. F., Sederias, J., Xu, H., Powers, J., Seymour, L. K., & Reiman, T. (n.d.). a phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Leukemia & lymphoma, 57(6), 1463–1466. http://access.bl.uk/ark:/81055/vdc_100034281744.0x00003e